Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

1.3K
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
1.3K
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

2.2K
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
2.2K
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

3.4K
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathfinder: a modified collaborative game for learning and team development.

Innovations in pharmacy·2026
Same author

Evaluating the compatibility, stability, and antimicrobial effectiveness of vancomycin and cefepime admixtures in peritoneal dialysis solutions.

Scientific reports·2026
Same author

Post-vaccine inflammation tracking: validation of a novel individualized digital inflammatory biomarker relative to serum biomarkers.

NPJ digital medicine·2026
Same author

Direct-to-Participant Enrollment in a Virtual Trial: Lessons Learned From the Heartline Study.

JACC. Advances·2026
Same author

Deep Learning-Enabled Diabetic Retinopathy Screening: A Techno-Clinical Revolution or Just More Artificial Intelligence Hype?

Diabetes care·2026
Same author

Diverging trajectories of trust in healthcare and on-line information seeking: what's next with LLMs.

NPJ digital medicine·2026

Related Experiment Video

Updated: May 4, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

2.9K

Cangrelor in percutaneous coronary intervention.

Julie H Oestreich1, Steven R Steinhubl

  • 1725 Rose Street, College of Pharmacy, University of Kentucky, Lexington, KY 40514, USA. jhoest2@email.uky.edu.

Expert Review of Clinical Pharmacology
|January 14, 2014
PubMed
Summary

Cangrelor, a new intravenous P2Y12 inhibitor, offers rapid platelet inhibition for percutaneous coronary intervention. Its unique properties suggest improved prevention of cardiac events in patients.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

6.1K

Related Experiment Videos

Last Updated: May 4, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

2.9K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

6.1K

Area of Science:

  • Cardiovascular Pharmacology
  • Thrombosis Research

Background:

  • P2Y12 receptor antagonists are crucial in preventing thrombotic events during percutaneous coronary intervention (PCI).
  • Existing oral thienopyridines (clopidogrel, prasugrel) have limitations including delayed onset and variable metabolism.

Purpose of the Study:

  • To evaluate cangrelor, a novel intravenous P2Y12 antagonist, for its efficacy and safety in PCI.
  • To highlight cangrelor's advantages over existing antiplatelet therapies.

Main Methods:

  • Cangrelor is an intravenous, reversible P2Y12 receptor antagonist currently in Phase III clinical trials.
  • Its pharmacokinetic and pharmacodynamic properties are being assessed in patients undergoing PCI.

Main Results:

  • Cangrelor demonstrates rapid onset of action and a short half-life following intravenous administration.
  • It achieves maximal inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation.
  • Cangrelor bypasses hepatic and renal metabolism, offering a distinct advantage.

Conclusions:

  • Cangrelor's unique profile, including rapid onset, short duration, and predictable pharmacodynamics, makes it a promising agent for PCI.
  • It offers a potential improvement in preventing adverse cardiac events compared to oral agents.
  • Its intravenous administration and lack of metabolism offer significant clinical benefits in cardiovascular patients.